{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-190489","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.406206+00:00","generated_at":"2026-06-13T05:36:02.868060+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acumen Pharmaceuticals prices public offering of 16.8M shares at $7.75/share","bullets":["Offering of 16,774,193 shares at $7.75 each; underwriters have 30-day option for up to 2,516,128 additional shares.","Underwriters include BofA Securities, Citigroup Global Markets, and Stifel; closing expected July 21, 2023.","Estimated offering expenses of ~$440,000 excluding underwriting discounts; proceeds for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-190489","json":"https://secwatch.observer/filing/0001193125-23-190489.json","markdown":"https://secwatch.observer/filing/0001193125-23-190489.md","text":"https://secwatch.observer/filing/0001193125-23-190489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523190489/0001193125-23-190489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523190489/d467661d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:36:02.868060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fce816f10e9919006a43c658ed9df66a0f492b9","claim":"Acumen Pharmaceuticals, Inc. entered into Underwriting Agreement with BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters (effective 2023-07-18).","evidence_excerpt":"On July 18, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters (the “Underwriters”), relating to a public offering (the “Offering”) of 16,774,193 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a price to the public of $7.75 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523190489/0001193125-23-190489-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"BofA Securities, Inc., Citigroup Global Markets Inc. and Stifel, Nicolas & Company, Incorporated, as representatives of the several underwriters"},{"label":"Effective","value":"2023-07-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}